The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Improving radiotherapy in cancer treatment: Promises and challenges
Open accessAbstract
// Helen H.W. Chen 1 and Macus Tien Kuo 1, 2 1 Division of Clinical Radiation Oncology, Department of Radiation Oncology, National Cheng Kung University Hospital, Department of Radiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence to: Macus Tien Kuo, email: tkuo@mdanderson.org Helen H.W. Chen, email: helen@mail.ncku.edu.tw Keywords: radiotherapy, DNA damage response, hypoxia, cancer genomics, immune check points Received: February 03, 2017 Accepted: April 18, 2017 Published: June 08, 2017 ABSTRACT Effective radiotherapy for cancer has relied on the promise of maximally eradicating tumor cells while minimally killing normal cells. Technological advancement has provided state-of-the-art instrumentation that enables delivery of radiotherapy with great precision to tumor lesions with substantial reduced injury to normal tissues. Moreover, better understanding of radiobiology, particularly the mechanisms of radiation sensitivity and resistance in tumor lesions and toxicity in normal tissues, has improved the treatment efficacy of radiotherapy. Previous mechanism-based studies have identified many cellular targets that can affect radiation sensitivity, notably reactive oxygen species, DNA-damaging response signals, and tumor microenvironments. Several radiation sensitizers and protectors have been developed and clinically evaluated; however, many of these results are inconclusive, indicating that improvement remains needed. In this era of personalized medicine in which patients’ genetic variations, transcriptome and proteomics, tumor metabolism and microenvironment, and tumor immunity are available. These new developments have provided opportunity for new target discovery. Several radiotherapy sensitivity-associated “gene signatures” have been reported although clinical validations are needed. Recently, several immune modifiers have been shown to associate with improved radiotherapy in preclinical models and in early clinical trials. Combination of radiotherapy and immunocheckpoint blockade has shown promising results especially in targeting metastatic tumors through abscopal response. In this article, we succinctly review recent advancements in the areas of mechanism-driven targets and exploitation of new targets from current radio-oncogenomic and radiation-immunotherapeutic approaches that bear clinical implications for improving the treatment efficacy of radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E., & Fitzgerald, K. A. (2009) · Nature · doi:10.1038/nature07725 · Cited by 2,627
Mechanisms and Functions of Inflammasomes
Lamkanfi, M., & Dixit, V. M. (2014) · Cell · doi:10.1016/j.cell.2014.04.007 · Cited by 2,503
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“The abscopal effects have been attributed to the induced inflammatory cytokines such as IL-1β, IL-6, and TNF-α released from the primary tumor site or nontumor cells such as endothelial cells and cancer associated fibroblasts (Figure 3) [115].”
BackgroundIrradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
Fernandes-Alnemri, T., Yu, J.-W., Datta, P., Wu, J., & Alnemri, E. S. (2009) · Nature · doi:10.1038/nature07710 · Cited by 1,831
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 1×
“When bound to its ligands PD-L1/PD-L2, they elicit a T-cell inhibitory signal through inhibition of T cells costimulastory receptor CD28 but not T cell receptor (TCR) as previously believed [119, 120].”
BackgroundDewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury
Azzam, E. I., Jay-Gerin, J.-P., & Pain, D. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.012 · Cited by 1,553
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., Maher, C. A., Fulton, R., Fulton, L., Wallis, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,146
Mutational signatures associated with tobacco smoking in human cancer
Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100 · cited 1×
“These observations suggest that exposures to mutagens such as ultraviolet light in melanoma and tobacco smoking [145] in NSCLC may increase mutational loads leading to increased immunogenic neoantigens production.”
BackgroundKlug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., Becker, A., Adam, M., Molls, M., Dunst, J., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.038 · Cited by 953
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Ang, K. K., Zhang, Q., Rosenthal, D. I., Nguyen-Tan, P. F., Sherman, E. J., Weber, R. S., Galvin, J. M., Bonner, J. A., Harris, J., El-Naggar, A. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5633 · Cited by 838
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer
Brizel, D. M., Wasserman, T. H., Henke, M., Strnad, V., Rudat, V., Monnier, A., Eschwege, F., Zhang, J., Russell, L., Oster, W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3339 · Cited by 828
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Radiation oncology in the era of precision medicine
Baumann, M., Krause, M., Overgaard, J., Debus, J., Bentzen, S. M., Daartz, J., Richter, C., Zips, D., & Bortfeld, T. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.18 · Cited by 812
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 684
Radiation-induced fibrosis: mechanisms and implications for therapy
Straub, J. M., New, J., Hamilton, C. D., Lominska, C., Shnayder, Y., & Thomas, S. M. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1974-6 · Cited by 677
Sharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
Pathogenetic mechanisms in radiation fibrosis
Yarnold, J., & Vozenin Brotons, M.-C. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.09.002 · Cited by 622
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615 · cited 1×
“Several pre-clinical studies have shown that radiotherapy can enhance CTC production in animal models, and CTC density is an independent biomarker for poor prognosis in NSCLC [85], esophageal squamous cell carcinoma [86], and breast cancers [87].”
BackgroundBOCS, Michailidou, K., kConFab Investigators, AOCS Group, NBCS, GENICA Network, Beesley, J., Lindstrom, S., Canisius, S., Dennis, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3242 · Cited by 598
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Overgaard, J., Sand Hansen, H., Overgaard, M., Bastholt, L., Berthelsen, A., Specht, L., Lindeløv, B., & Jørgensen, K. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(97)00220-x · Cited by 573
Garnett, C. T., Palena, C., Chakarborty, M., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1525 · Cited by 557
Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome
Brizel, D. M., Dodge, R. K., Clough, R. W., & Dewhirst, M. W. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00102-4 · Cited by 548
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481
Saunders, M., Dische, S., Barrett, A., Harvey, A., Griffiths, G., & Parmar, M. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00087-0 · Cited by 480
Overgaard, J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.03.004 · Cited by 456
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
Strønen, E., Toebes, M., Kelderman, S., van Buuren, M. M., Yang, W., van Rooij, N., Donia, M., Böschen, M.-L., Lund-Johansen, F., Olweus, J., et al. (2016) · Science · doi:10.1126/science.aaf2288 · Cited by 445
Abscopal effects of radiation therapy: A clinical review for the radiobiologist
Siva, S., MacManus, M. P., Martin, R. F., & Martin, O. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2013.09.018 · Cited by 441
Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer
Fyles, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.680 · Cited by 397
Yamamori, T., Yasui, H., Yamazumi, M., Wada, Y., Nakamura, Y., Nakamura, H., & Inanami, O. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.04.033 · Cited by 396
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., Ray, R., Bashir, N., Bridgewater, J. A., Geh, J. I., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70136-0 · Cited by 381
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380
Grimaldi, A. M., Simeone, E., Giannarelli, D., Muto, P., Falivene, S., Borzillo, V., Giugliano, F. M., Sandomenico, F., Petrillo, A., Curvietto, M., et al. (2014) · OncoImmunology · doi:10.4161/onci.28780 · Cited by 379
Current clinical trials testing the combination of immunotherapy with radiotherapy
Kang, J., Demaria, S., & Formenti, S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0156-7 · Cited by 371
Targeting Inflammation in Cancer Prevention and Therapy
Todoric, J., Antonucci, L., & Karin, M. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0209 · Cited by 354
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0127 · Cited by 345
Lannering, B., Rutkowski, S., Doz, F., Pizer, B., Gustafsson, G., Navajas, A., Massimino, M., Reddingius, R., Benesch, M., Carrie, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8719 · Cited by 333
Cell death induced by the Fas/Fas ligand pathway and its role in pathology
Waring, P., & Müllbacher, A. (1999) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1999.00837.x · Cited by 322
Tang, C., Welsh, J. W., de Groot, P., Massarelli, E., Chang, J. Y., Hess, K. R., Basu, S., Curran, M. A., Cabanillas, M. E., Subbiah, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1432 · Cited by 321
The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling
Sullivan, L. B., Martinez-Garcia, E., Nguyen, H., Mullen, A. R., Dufour, E., Sudarshan, S., Licht, J. D., Deberardinis, R. J., & Chandel, N. S. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.003 · Cited by 304
Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295
Mladenov, E., Magin, S., Soni, A., & Iliakis, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00113 · Cited by 290
Fumarate induces redox-dependent senescence by modifying glutathione metabolism
Zheng, L., Cardaci, S., Jerby, L., MacKenzie, E. D., Sciacovelli, M., Johnson, T. I., Gaude, E., King, A., Leach, J. D. G., Edrada-Ebel, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms7001 · Cited by 281
Srikrishna, G., & Freeze, H. H. (2009) · Neoplasia · doi:10.1593/neo.09284 · Cited by 275
Wang, X., Schoenhals, J. E., Li, A., Valdecanas, D. R., Ye, H., Zang, F., Tang, C., Tang, M., Liu, C.-G., Liu, X., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3142 · Cited by 261
Trpkov, K., Hes, O., Agaimy, A., Bonert, M., Martinek, P., Magi-Galluzzi, C., Kristiansen, G., Lüders, C., Nesi, G., Compérat, E., et al. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000617 · Cited by 255
Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways
Morgan, M. A., & Lawrence, T. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3229 · Cited by 250
Morrison, R., Schleicher, S. M., Sun, Y., Niermann, K. J., Kim, S., Spratt, D. E., Chung, C. H., & Lu, B. (2011) · Journal of Oncology · doi:10.1155/2011/941876 · Cited by 247
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., Saha, S., Shura, L., & Knox, S. J. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.07.005 · Cited by 233
Chandra, R. A., Wilhite, T. J., Balboni, T. A., Alexander, B. M., Spektor, A., Ott, P. A., Ng, A. K., Hodi, F. S., & Schoenfeld, J. D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046028 · Cited by 229
Nordsmark, M., Alsner, J., Keller, J., Nielsen, O. S., Jensen, O. M., Horsman, M. R., & Overgaard, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1728 · Cited by 226
Morris, L. G. T., Chandramohan, R., West, L., Zehir, A., Chakravarty, D., Pfister, D. G., Wong, R. J., Lee, N. Y., Sherman, E. J., Baxi, S. S., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1790 · Cited by 223
Zhao, S. G., Chang, S. L., Spratt, D. E., Erho, N., Yu, M., Ashab, H. A.-D., Alshalalfa, M., Speers, C., Tomlins, S. A., Davicioni, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30491-0 · Cited by 213
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
Eschrich, S. A., Fulp, W. J., Pawitan, Y., Foekens, J. A., Smid, M., Martens, J. W. M., Echevarria, M., Kamath, V., Lee, J.-H., Harris, E. E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0891 · Cited by 208
Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity
Dansen, T. B., Smits, L. M. M., van Triest, M. H., de Keizer, P. L. J., van Leenen, D., Koerkamp, M. G., Szypowska, A., Meppelink, A., Brenkman, A. B., Yodoi, J., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.194 · Cited by 201
Antigen processing and immune regulation in the response to tumours
Reeves, E., & James, E. (2017) · Immunology · doi:10.1111/imm.12675 · Cited by 198
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A.-T. (2016) · Nature Genetics · doi:10.1038/ng.3677 · Cited by 166
Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies
Milas, L., Fan, Z., Andratschke, N. H., & Ang, K. K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.08.035 · Cited by 162
Flechsig, P., Dadrich, M., Bickelhaupt, S., Jenne, J., Hauser, K., Timke, C., Peschke, P., Hahn, E. W., Gröne, H., Yingling, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2855 · Cited by 155
Antitumor immune responses induced by ionizing irradiation and further immune stimulation
Frey, B., Rubner, Y., Kulzer, L., Werthmöller, N., Weiss, E., Fietkau, R., & Gaipl, U. S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1474-y · Cited by 150
Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie, M. J., & Brown, J. M. (1993) · PubMed · Cited by 143
Sun, Y., Clair, D. K. S., Xu, Y., Crooks, P. A., & Clair, W. H. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4572 · Cited by 137
Svensson, J. P., Stalpers, L. J. A., Esveldt, R. E., Franken, N. A. P., HAVEMAN, J., Klein, B., Turesson, I., Vrieling, H., & Giphart-Gassler, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030422 · Cited by 129
Circulating tumour cells—monitoring treatment response in prostate cancer
Miyamoto, D. T., Sequist, L. V. D., & Lee, R. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.82 · Cited by 122
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
Mandal, R., & Chan, T. A.-T. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0146 · Cited by 122
The radiosensitivity index predicts for overall survival in glioblastoma
Ahmed, K. A., Chinnaiyan, P., Fulp, W. J., Eschrich, S. A., Torres–Roca, J. F., & Caudell, J. J. (2015) · Oncotarget · doi:10.18632/oncotarget.5437 · Cited by 118
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. J. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 113
Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
Proia, D. A., & Bates, R. C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3263 · Cited by 112
Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report
Okuma, K., Yamashita, H., Niibe, Y., Hayakawa, K., & Nakagawa, K. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-111 · Cited by 111
Jacobson, G. M., Bhatia, S. K., Smith, B. J., Button, A. M., Bodeker, K. L., & Buatti, J. M. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.06.042 · Cited by 101
PARP Inhibitors for Cancer Therapy
Lin, K. Y., & Kraus, W. L. (2017) · Cell · doi:10.1016/j.cell.2017.03.034 · Cited by 101
Pitroda, S. P., Pashtan, I. M., Logan, H. L., Budke, B., Darga, T. E., Weichselbaum, R. R., & Connell, P. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008291 · Cited by 99
Mobilization of Viable Tumor Cells Into the Circulation During Radiation Therapy
Martin, O. A., Anderson, R. L., Russell, P. A., Cox, R. A., Ivashkevich, A. N., Swierczak, A., Doherty, J. P., Jacobs, D., Smith, J., Siva, S., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.10.033 · Cited by 96
Richardson, R. B., & Harper, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7412 · Cited by 93
Epigenetics in radiation-induced fibrosis
Weigel, C., Schmezer, P., Plass, C., & Popanda, O. (2014) · Oncogene · doi:10.1038/onc.2014.145 · Cited by 91
An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Peitzsch, C., Cojoc, M., Hein, L., Kurth, I., Mäbert, K., Trautmann, F., Klink, B., Schröck, E., Wirth, M. P., Krause, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2116 · Cited by 87
Relationship and interactions of curcumin with radiation therapy
Verma, V. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i3.275 · Cited by 85
Recruitment of Circulating Breast Cancer Cells Is Stimulated by Radiotherapy
Vilalta, M., Rafat, M., Giaccia, A. J., & Graves, E. E. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.011 · Cited by 76
Tateishi, Y., Sasabe, E., Ueta, E., & Yamamoto, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.039 · Cited by 75
Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Sharma, A., Bode, B., Studer, G., Moch, H., Okoniewski, M. J., Knuth, A. K., von Boehmer, L., & van den Broek, M. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0352 · Cited by 69
Hofer, M., Falk, M., Komůrková, D., Falková, I., Bačı́ková, A., Klejdus, B., Pagáčová, E., Štefančíková, L., Weiterová, L., Angelis, K. J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01628 · Cited by 69
Mayer, C., Popanda, O., Greve, B., Fritz, E., Illig, T., Eckardt‐Schupp, F., Gomolka, M., Benner, A., & Schmezer, P. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.12.006 · Cited by 68
The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice
Sohn, S.-H., Lee, J. M., Park, S., Yoo, H., Kang, J. W., Shin, D., Jung, K., Lee, Y., Cho, J., & Bae, H. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.02.019 · Cited by 67
Licandro, G., Khor, H. L., Beretta, O., Lai, J., Derks, H., Laudisi, F., Conforti‐Andreoni, C., Qian, H. L., Teng, G. G., Ricciardi‐Castagnoli, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242918 · Cited by 64
Thomson, D. J., Yang, H., Baines, H., Miles, E. A., Bolton, S., West, C., & Slevin, N. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.003 · Cited by 64
Hauser, S. H., Calorini, L., Wazer, D. E., & Gattoni‐Celli, S. (1993) · PubMed · Cited by 63
Redox Proteins and Radiotherapy
Zhang, Y., & Martin, S. G. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.02.003 · Cited by 61
Boivin, A., Hanot, M., Malésys, C., Maalouf, M., Rousson, R., Rodriguez‐Lafrasse, C., & Ardail, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014558 · Cited by 58
Kriegs, M., Gurtner, K., Can, Y., Brammer, I., Rieckmann, T., Oertel, R., Wysocki, M., Dorniok, F., Gal, A., Grob, T. J., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.018 · Cited by 58
New treatment option for ovarian cancer: PARP inhibitors
Meehan, R. S., & Chen, A. P. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0024-7 · Cited by 58
Chau, N. G., Li, Y. Y., Jo, V. Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2314 · Cited by 57
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Kan, C. E., & Zhang, J. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.05.037 · Cited by 56
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
Mouw, K. W., Cleary, J. M., Reardon, B. M., Pike, J. W., Braunstein, L. Z., Kim, J., Amin‐Mansour, A., Miao, D., Damish, A. W., Chin, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2017 · Cited by 51
Woolston, C. M., Storr, S. J., Ellis, I. O., Morgan, D. A. L., & Martin, S. G. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.029 · Cited by 49
HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas
Ernst, A., Anders, H., Kapfhammer, H., Orth, M., Hennel, R., Seidl, K., Winssinger, N., Belka, C., Unkel, S., & Lauber, K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.024 · Cited by 48
Effect of Dimethyl Fumarate on the Radiation Sensitivity of Mammalian Cells in Vitro
Held, K. D., Epp, E. R., Clark, E. P., & Biaglow, J. E. (1988) · Radiation Research · doi:10.2307/3577299 · Cited by 48
Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy
Park, J., Thomas, S., & Münster, P. N. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 47
Šímová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Štěpánek, I., Bubenik, J., & Reiniš, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.428 · Cited by 47
Forrester, H. B., Li, J., Leong, T., McKay, M. J., & Sprung, C. N. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.03.007 · Cited by 44
Emerging Treatment Paradigms in Radiation Oncology
Le, Q., Shirato, H., Giaccia, A. J., & Koong, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1191 · Cited by 42
Vlková, V., Štěpánek, I., Hrušková, V., Šenigl, F., Mayerová, V., Šrámek, M., Šímová, J., Bieblová, J., Indrová, M., Hejhal, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2222 · Cited by 41
Su, P., Wu, M., Wang, H., Lee, C.-L., Huang, W., Wu, C., Chang, H., Chao, Y., Tseng, C., Chiu, T.-K., et al. (2016) · Scientific Reports · doi:10.1038/srep31423 · Cited by 40
Hümmerich, J., Werle‐Schneider, G., Popanda, O., Celebi, O., Chang-Claude, J., Kropp, S., Mayer, C., Debus, J., Bartsch, H., & Schmezer, P. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000600883302 · Cited by 33
Radiation Therapy and Immunotherapy: Growing Pains
Golden, E. B., & Formenti, S. C. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.09.018 · Cited by 30
Kinzel, L., Ernst, A., Orth, M., Albrecht, V. S., Hennel, R., Brix, N., Frey, B., Gaipl, U. S., Zuchtriegel, G., Reichel, C. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9774 · Cited by 26
General Strategies in Inflammasome Biology
Dubois, H., Wullaert, A., & Lamkanfi, M. (2016) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-41171-2_1 · Cited by 26
More Lessons Learned From the Suffocation of Hypoxia
Ang, K. K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3085 · Cited by 25
Dorling, L., Barnett, G. C., Michailidou, K., Coles, C. E., Burnet, N. G., Yarnold, J. R., Elliott, R. M., Dunning, A. M., Pharoah, P. D. P., & West, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1080 · Cited by 24
Bhardwaj, R., Sharma, P. K., Jadon, S. P. S., & Varshney, R. K. (2012) · Tumor Biology · doi:10.1007/s13277-012-0335-1 · Cited by 21
Blood Gene Expression Profiling of Breast Cancer Survivors Experiencing Fibrosis
Landmark‐Høyvik, H., Dumeaux, V., Reinertsen, K. V., Edvardsen, H., Fosså, S. D., & Børresen‐Dale, A. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.052 · Cited by 15
Can Selective MHC Downregulation Explain the Specificity and Genetic Diversity of NK Cell Receptors?
Carrillo-Bustamante, P., Keşmir, C., & de Boer, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00311 · Cited by 11
Cited by
Molecular mechanisms linking exercise to cancer prevention and treatment
Hojman, P., Gehl, J., Christensen, J. F., & Pedersen, B. K. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.015 · Cited by 600
Recent advances in nanoparticle-based photothermal therapy for breast cancer
Alamdari, S. G., Amini, M., Jalilzadeh, N., Baradaran, B., Mohammadzadeh, R., Mokhtarzadeh, A., & Oroojalian, F. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.050 · Cited by 290
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Rational Design of Biomaterials to Potentiate Cancer Thermal Therapy
Zhu, Y., Li, Q., Wang, C., Hao, Y., Yang, N., Chen, M., Ji, J., Feng, L., & Liu, Z. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00822 · Cited by 163
Usoltseva, R. V., Shevchenko, N. M., Malyarenko, O. S., Anastyuk, S. D., Kasprik, A. E., Zvyagintsev, N. V., & Ermakova, S. P. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.05.079 · Cited by 73
Metadata
- Authors
- Chen, H. H. W., & Kuo, M. T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-06-08
- Volume
- 8
- Issue
- 37
- Pages
- 62742-62758
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2623802897
- Cited by
- 372
- References
- 140
- FWCI
- 14.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.